Key Summary Prices are anticipated to fall 30-50 percent initially, with the potential for deeper cuts of up to 70-75 percent over time Dr Reddy's could be the first generic player among Indian companies to launch in Canada, and Sun Pharma in Brazil The launch of generic semaglutide is projected to boost overall Indian Pharmaceutical Market (IPM) growth by 0.5-1 percent The impending patent expiry of semaglutide drugs, used to treat diabetes and obesity, across India, emerging markets and select regulated markets such as Canada and Brazil, is expected to unlock a huge revenue opportunity, says a report
Moving forward, I dont believe that its going to drive the price point down anytime soon. Lilly told Fortune that it is continuing to focus on making our affordability solutions available for insured adults who already have coverage for Mounjaro
If the proposed rule is finalized, negotiated prices on Ozempic, Wegovy and Rybelsus would be applicable to that rule
This makes independent testing data, like the Finnrick results discussed above, particularly valuable